DISSEMINATED INFECTION DUE TO *Fusarium sp.* 
IN A PATIENT WITH CHRONIC GRANULOMATOUS DISEASE

SHAHINDOKHT BASIRI DJAHROMI, ALI ASGHAR KHAKSAR, MOJGAN VAZIRI KASHANI,* AND SAHBA ARSHI**

*From the Department of Medical Mycology, Pasteur Institute of Iran, the *Section of Pathology, Pasteur Institute of Iran, and the **Department of Pediatrics, Hazrat Rasool Acram Hospital, Iran University of Medical Sciences, Tehran, Islamic Republic of Iran.*

**ABSTRACT**

The present report discusses disseminated fusariosis in a 15 year old boy with chronic granulomatous disease (CGD). He was admitted to the Hazrat Rasool Acram Hospital in November 1995, with a chronic wound in the right ankle and buttock area. Antibacterial therapy was started, but there was no response. The patient was still febrile. Chest x-ray revealed parahilar lesions in both lungs. Tissue biopsy and broncho-alveolar lavage were performed and the specimens were sent to Pasteur Institute. In both specimens, *Fusarium sp.* was recognized as the pathologic agent by direct smear and culture techniques. The patient underwent antifungal therapy receiving amphotericin B and oral ketoconazole. The result of this treatment suggests that aggressive management of fusariosis offers the best chance of survival. This paper reports the first case of disseminated fusariosis in Iran.

**Keywords**: Fungal infection, *Fusarium sp.*, Chronic granulomatous disease.


**INTRODUCTION**

*Fusarium sp.* is a common soil organism and has been reported most frequently as an agent of mycotic keratitis. It is usually considered an opportunistic fungus in man; however, there have been a number of recent reports in which *Fusarium sp.* caused systemic fungal infections. Systemic infection with *Fusarium sp.* occurs predominantly in immunocompromised patients.

Several cases of onycomycosis and keratitis with *Fusarium Sp.* have been reported in Iran, but the present case is the first report of disseminated fusariosis.

**Case report**

A 15 year old boy, who was a known case of CGD, was admitted to Hazrat Rasool Acram Hospital on November 5th, 1995 with an oozing erythematous, edematous and painful lesion of the right ankle area (Fig. 6). His problem began when he was 2 years old with an ulcerative and infectious lesion in the neck area, which was recurrent. Despite the negative cultures of lymph node and fistular discharges, he underwent a clinical trial of anti-TB therapy for 30 months. This treatment trial made him free of symptoms within a year. In 1992 he had an ankle sprain. After removal of the cast, the area began to swell and ulcerate. The lesion exacerbated gradually and fistulization occurred. Treatment with cephalothin and gentamicin was begun, but the response was not satisfactory. So this drug regimen was replaced by co-trimoxazole and erythromycin. Initially the lesions healed but they recurred about 5
Disseminated Fusarium Infection in CGD

Fig. 1. Microscopy of broncho-alveolar lavage, showing Fusarium sp. hyphae. x 400.

months later. In 1993 the patient was referred to the pediatric medical center, where CGD was definitively diagnosed (NBT= 0)*. The patient underwent treatment with cephalixin, co-trimoxazole and gamma interferon. He had two other hospital admissions in Sept. 1994 and Feb. 1995. Debridement of the ankle lesion and an iliac bone graft were performed, followed by antibiotic therapy. On November 5th, 1995, the patient was admitted again in Hazrat Rasool Acram Hospital with ulcers on the right ankle and buttock area. The painful lesion of the right ankle was infiltrating, edematous and erythematous, and the tip was fistulized and oozing.

On physical examination he was pale and seemed anemic. He had high grade fever and generalized lymphadenopathy, associated with an itching maculopapular rash on his lower extremities and trunk. X-ray revealed osseous and ankle joint involvement. There was no response to antibacterial treatment with cephalothin (17 days) and amikacin (14 days). The patient was still febrile. Chest x-ray revealed parahilar lesions in both lungs. As there was no response to antibacterial therapy, fungal infections were suspected. A biopsy specimen of the lesion and B.A.L. (broncho-alveolar lavage) were performed and sent to Pasteur Institute. The specimens for mycological study were biopsy material of the lesion, B.A.L., and blood. Specimens were directly examined with 10% KOH. The biopsy specimens and B.A.L. showed the presence of branching hyaline septated hyphae (Figs. 1-3). The tissue sections were stained by hematoxylin and eosin and periodic acid schiff stains. Sections revealed a granulomatous reaction.

Ground tissue and B.A.L. were cultured on sabouraud dextrose agar, sabouraud dextrose agar with chloramphenicol (50 mg/mL), blood agar and brain heart infusion agar (BBL). Duplicate cultures on each medium were incubated at 37°C and 30°C. Culture of the specimens gave rise to Fusarium sp. The blood culture was negative.

Microscopic features of the isolates were studied by slide culture preparation. Fusarium sp. colonies were identified as initially cotton-white colonies which turned purple in the substratum (Fig. 4).

Microscopic examination showed hyaline septate hyphae with conidiophores borne singly or in groups, banana-shaped macroconidia and oval or elongated single-cell microconidia (Fig. 5).

The patient underwent a 40-day course of intravenous amphotericin B (1 mg/kg/day), and oral ketoconazole for a total period of 50 days (150 mg/day). Following antifungal

*NBT= Nitro blue tetrazolin. Used for diagnosis and screening of chronic granulomatous disease and for detection of carrier state.*
therapy, the lesions subsided and the patient's condition improved clinically. A skin graft was performed, and the patient was discharged in January 1996.

DISCUSSION

This case of disseminated *Fusarium* sp. infection is reported for the first time in Iran from Pasteur Institute. Fungi of the genus *Fusarium* can cause disease in plants and animals. In man there are reports of superficial infections in various sites such as the skin, cornea and nails and of localized organ infections including endophthalmitis, arthritis, cystitis, peritonitis, and keratitis. However, systemic infection is rare. The first description of disseminated fusariosis was in 1973 in a child with acute lymphocytic leukemia.

Systemic fungal infections with *Fusarium* sp. occur predominantly in immunocompromised patients. This paper reports a case of disseminated fusariosis involving the skin and lungs, in a patient with chronic granulomatous disease. In the immunocompromised host however, especially in those in whom neutrophil and macrophage functions are deficient, it can cause devastating systemic infections. Patients with CGD have disorders of neutrophil and monocyte oxidative metabolism. CGD results from inherited defects in the genes encoding the several components of NADPH oxidase, which generates superoxide. Patients with chronic granulomatous disease are unable to generate a "respiratory burst" after stimulation of neutrophils and monocytes and are therefore unable to
Disseminated Fusarium Infection in CGD

kill certain microorganisms. "Respiratory burst" results in the generation of superoxide (O2·−), hydrogen peroxide (H2O2), and hypochlorite (OCl−). Leukocytes from patients with CGD have severely diminished hydrogen peroxide production. Although CGD is rare, occurring in about 1 in one million individuals, it is an important model of defective neutrophil oxidative metabolism.

The homogeneity of the clinical presentation of fusarial infection is noteworthy. The most important clinical features are painful cutaneous nodules which are initially reddish but become rapidly necrotic. Severe myalgia is commonly seen.1,6

Our patient also had an infiltrative, edematous, erythematous, painful lesion and flaccid pustules on his right ankle. Some of the pustules developed central necrosis. The course of the infection in our patient was similar to that of most cases previously reported.

Our patient survived with antifungal treatment. This treatment included amphotericin B (1 mg/kg/day), and oral ketoconazole (150 mg/day). Amphotericin B remains the standard treatment.8

From this case and from a review of the literature, it appears that synergic antifungal agents may be beneficial in successful treatment of fusariosis in the compromised host.

REFERENCES